Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
| Autor: | Andre, Thierry, Elez, Elena, Van Cutsem, Eric, Jensen, Lars Henrik, Bennouna, Jaafar, Mendez, Guillermo, Schenker, Michael, De La Fouchardiere, Christelle, Limon, Maria Luisa, Yoshino, Takayuki, Li, Jin, Lenz, Heinz-Josef, Manzano Mozo, Jose Luis, Tortora, Giampaolo, Garcia-Carbonero, Rocio, Cela, Elvis, Yang, Yingsi, Lei, Ming, Jin, Lixian, Lonardi, Sara |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pLBA768-LBA768, 6p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|